DE1115350B
(de)
|
1959-04-17 |
1961-10-19 |
Siemens Ag |
Selbstschalter, insbesondere Leitungsschutz-schalter, mit einem aus einem Kniegelenk bestehenden Antriebsmechanismus fuer das Schaltorgan
|
GB971307A
(en)
|
1961-03-02 |
1964-09-30 |
Wellcome Found |
5-anilinopyrimidines
|
GB1127875A
(en)
|
1967-03-23 |
1968-09-18 |
Parke Davis & Co |
4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils
|
US3949002A
(en)
|
1970-11-13 |
1976-04-06 |
Imperial Chemical Industries Limited |
Process for producing sulfone containing thiophenols
|
US3818024A
(en)
|
1972-02-16 |
1974-06-18 |
Velsicol Chemical Corp |
Benzothiazol substituted thiadiazolidines
|
CH565887A5
(sr)
|
1972-08-22 |
1975-08-29 |
Ciba Geigy Ag |
|
US3939122A
(en)
|
1973-04-11 |
1976-02-17 |
Bayer Aktiengesellschaft |
Process for the preparation of compounds which contain hydantoin rings
|
FR2337554A1
(fr)
|
1976-01-08 |
1977-08-05 |
Buzas Andre |
Nouveaux derives de la pyrazolidinedione
|
JPS5915247B2
(ja)
|
1976-09-14 |
1984-04-09 |
古河電気工業株式会社 |
電力制御による走行体の定位置停止方式
|
US4093624A
(en)
|
1977-01-31 |
1978-06-06 |
Icn Pharmaceuticals, Inc. |
1,2,4-Thiadiazolidine-3,5-dione
|
FR2396549A2
(fr)
|
1977-07-06 |
1979-02-02 |
Buzas Andre |
Nouveaux derives de la pyrazolidinedione
|
US4256758A
(en)
|
1979-06-11 |
1981-03-17 |
Merck & Co., Inc. |
4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
|
US4298743A
(en)
|
1979-09-11 |
1981-11-03 |
Merck & Co., Inc. |
4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
|
US4296237A
(en)
|
1979-09-11 |
1981-10-20 |
Merck & Co., Inc. |
4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
|
US4432992A
(en)
|
1979-11-05 |
1984-02-21 |
Merck & Co., Inc. |
4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
|
US4366189A
(en)
|
1979-12-21 |
1982-12-28 |
Ciba-Geigy Corporation |
4-Heterocyclyl-4'-vinylstilbenes
|
JPS59177557A
(ja)
|
1983-03-28 |
1984-10-08 |
Fuji Photo Film Co Ltd |
ハロゲン化銀カラ−写真感光材料
|
DE3406329A1
(de)
|
1984-02-22 |
1985-08-22 |
Merck Patent Gmbh, 6100 Darmstadt |
Pyridone
|
US4816454A
(en)
|
1984-09-21 |
1989-03-28 |
Cassella Aktiengesellschaft |
4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
|
US5514691A
(en)
|
1993-05-20 |
1996-05-07 |
Immunopharmaceutics, Inc. |
N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5103014A
(en)
|
1987-09-30 |
1992-04-07 |
American Home Products Corporation |
Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
|
AU606808B2
(en)
|
1988-06-29 |
1991-02-14 |
Otsuka Pharmaceutical Factory, Inc. |
Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
|
FR2662162B1
(fr)
|
1990-05-18 |
1995-01-20 |
Adir |
Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
|
GB9012936D0
(en)
|
1990-06-11 |
1990-08-01 |
Fujisawa Pharmaceutical Co |
Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
|
US5254715A
(en)
|
1990-11-07 |
1993-10-19 |
Warner-Lambert Company |
Aminosulfonyl carbamates
|
JP3108097B2
(ja)
|
1991-01-21 |
2000-11-13 |
塩野義製薬株式会社 |
3−ベンジリデン−1−カルバモイル−2−ピロリドン類縁体
|
US5162360A
(en)
|
1991-06-24 |
1992-11-10 |
Warner-Lambert Company |
2-heteroatom containing urea and thiourea ACAT inhibitors
|
GB9816837D0
(en)
|
1998-08-04 |
1998-09-30 |
Zeneca Ltd |
Amide derivatives
|
GB9125515D0
(en)
|
1991-11-29 |
1992-01-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5658924A
(en)
|
1992-12-01 |
1997-08-19 |
The Green Cross Corporation |
1,8-naphthyridin-2-one derivative and use thereof
|
DE4302702A1
(de)
|
1993-02-01 |
1994-08-04 |
Bayer Ag |
Arylaminosulfonylharnstoffe
|
WO1994021617A1
(en)
|
1993-03-19 |
1994-09-29 |
Dowelanco |
A process for preparing halogenated isothiazoles
|
CA2159344A1
(en)
|
1993-03-30 |
1994-10-13 |
Minoru Moriwaki |
Cell adhesion inhibitor and thienotriazolodiazepine compound
|
WO1994024095A1
(en)
|
1993-04-16 |
1994-10-27 |
Abbott Laboratories |
Immunosuppressive agents
|
CA2123728A1
(en)
|
1993-05-21 |
1994-11-22 |
Noriyoshi Sueda |
Urea derivatives and their use as acat inhibitors
|
WO1995006044A1
(en)
|
1993-08-20 |
1995-03-02 |
Smithkline Beecham Plc |
Amide and urea derivatives as 5ht1d receptor antagonists
|
DE4337847A1
(de)
|
1993-11-05 |
1995-05-11 |
Bayer Ag |
Substituierte Phenylaminosulfonylharnstoffe
|
AU1108395A
(en)
|
1993-12-07 |
1995-06-27 |
Smithkline Beecham Plc |
Heterocyclic biphenylylamides useful as 5ht1d antagonists
|
DE4343831A1
(de)
|
1993-12-22 |
1995-06-29 |
Magyar Tudomanyos Akademia |
Substituierte Sulfonylharnstoffe
|
FR2715155B1
(fr)
|
1994-01-19 |
1996-07-26 |
Mayoly Spindler |
Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation.
|
DE4414840A1
(de)
|
1994-04-28 |
1995-11-02 |
Bayer Ag |
Substituierte Phenylaminosulfonylharnstoffe
|
WO1995034540A1
(en)
|
1994-06-15 |
1995-12-21 |
Otsuka Pharmaceutical Company, Limited |
Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators
|
KR100417508B1
(ko)
|
1994-11-24 |
2004-03-18 |
바실리어 파마슈티카 아게 |
신규한벤질피리미딘
|
US5494925A
(en)
|
1994-12-02 |
1996-02-27 |
Sterling Winthrop Inc. |
2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
|
AU697361B2
(en)
|
1994-12-22 |
1998-10-01 |
Smithkline Beecham Plc |
Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists
|
SI0808312T1
(sr)
|
1995-02-02 |
2001-02-28 |
Smithkline Beecham Plc |
|
US5716542A
(en)
|
1995-04-24 |
1998-02-10 |
Takasago International Corporation |
Liquid crystal compound and liquid crystal composition containing the same
|
US6123964A
(en)
*
|
1995-10-27 |
2000-09-26 |
Merck & Co., Inc. |
Wet granulation formulation of a growth hormone secretagogue
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
GB9605945D0
(en)
|
1996-03-21 |
1996-05-22 |
Smithkline Beecham Plc |
Novel compounds
|
GB9607219D0
(en)
|
1996-04-04 |
1996-06-12 |
Smithkline Beecham Plc |
Novel compounds
|
EP0902782A1
(en)
|
1996-04-23 |
1999-03-24 |
Vertex Pharmaceuticals Incorporated |
Urea derivatives as inhibitors of impdh enzyme
|
US6147088A
(en)
|
1996-05-20 |
2000-11-14 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
AU735545B2
(en)
|
1996-05-24 |
2001-07-12 |
Neurosearch A/S |
Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
|
GB9623833D0
(en)
|
1996-11-16 |
1997-01-08 |
Zeneca Ltd |
Chemical compound
|
US6020357A
(en)
|
1996-12-23 |
2000-02-01 |
Dupont Pharmaceuticals Company |
Nitrogen containing heteroaromatics as factor Xa inhibitors
|
ATE230742T1
(de)
|
1997-03-27 |
2003-01-15 |
Great Lakes Chemical Europ |
2-(2'-hydroxphenyl)-benzotriazole und ihre verwendung als lichtschutzmittel für organische polymere
|
EP1019040B1
(en)
|
1997-05-23 |
2004-09-29 |
Bayer Corporation |
Aryl ureas for the treatment of inflammatory or immunomodulatory diseases
|
US6187799B1
(en)
|
1997-05-23 |
2001-02-13 |
Onyx Pharmaceuticals |
Inhibition of raf kinase activity using aryl ureas
|
US6294573B1
(en)
|
1997-08-06 |
2001-09-25 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
US6235786B1
(en)
|
1997-08-06 |
2001-05-22 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
CA2300051A1
(en)
|
1997-09-23 |
1999-04-01 |
George Robert Brown |
Amide derivatives for the treatment of diseases mediated by cytokines
|
IT1295933B1
(it)
|
1997-10-30 |
1999-05-28 |
Great Lakes Chemical Italia |
2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
|
AU1367599A
(en)
|
1997-11-03 |
1999-05-24 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
ES2155817T3
(es)
|
1997-12-22 |
2007-06-16 |
Bayer Pharmaceuticals Corp. |
Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
|
US20070244120A1
(en)
|
2000-08-18 |
2007-10-18 |
Jacques Dumas |
Inhibition of raf kinase using substituted heterocyclic ureas
|
ES2155045T3
(es)
|
1997-12-22 |
2007-02-01 |
Bayer Pharmaceuticals Corp. |
Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
|
US20080300281A1
(en)
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
JP4437270B2
(ja)
|
1997-12-22 |
2010-03-24 |
バイエル コーポレイション |
置換複素環式尿素を用いたrafキナーゼの阻害
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
JP4403482B2
(ja)
|
1997-12-22 |
2010-01-27 |
バイエル コーポレイション |
置換複素環尿素合成のための中間体およびその製造方法
|
NZ333399A
(en)
|
1997-12-24 |
2000-05-26 |
Sankyo Co |
Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
|
SI0928790T1
(en)
|
1998-01-02 |
2003-06-30 |
F. Hoffmann-La Roche Ag |
Thiazole derivatives
|
JPH11209350A
(ja)
|
1998-01-26 |
1999-08-03 |
Eisai Co Ltd |
含窒素複素環誘導体およびその医薬
|
ATE234099T1
(de)
|
1998-04-24 |
2003-03-15 |
Leuven K U Res & Dev |
Immununterdrückende effekte von 8 substituierten xanthinderivaten
|
SK286123B6
(sk)
|
1998-05-15 |
2008-04-07 |
Astrazeneca Ab |
Benzamidové deriváty, spôsob ich prípravy, farmaceutická kompozícia a ich použitie na prípravu liečiva na liečenie chorôb sprostredkovaných cytokínmi
|
US6197599B1
(en)
|
1998-07-30 |
2001-03-06 |
Guorong Chin |
Method to detect proteins
|
KR20010072080A
(ko)
|
1998-07-31 |
2001-07-31 |
쓰끼하시 다미까따 |
페닐아졸 화합물, 그의 제조 방법 및 고지혈증용 약제
|
WO2000018738A1
(en)
|
1998-09-25 |
2000-04-06 |
Astrazeneca Ab |
Benzamide derivatives and their use as cytokine inhibitors
|
ES2234300T3
(es)
|
1998-10-08 |
2005-06-16 |
Smithkline Beecham Plc |
3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
|
GB9823873D0
(en)
|
1998-10-30 |
1998-12-30 |
Pharmacia & Upjohn Spa |
2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
DE60014603T2
(de)
|
1999-03-12 |
2006-02-16 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
JP2000275886A
(ja)
|
1999-03-23 |
2000-10-06 |
Konica Corp |
電子写真感光体、それを用いたプロセスカートリッジ及び画像形成装置
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US6410254B1
(en)
|
1999-05-18 |
2002-06-25 |
Cytokinetics |
Compositions and assays utilizing ADP or phosphate for detecting protein modulators
|
EP1185512A2
(en)
|
1999-05-24 |
2002-03-13 |
Cor Therapeutics, Inc. |
INHIBITORS OF FACTOR Xa
|
JP3972163B2
(ja)
|
1999-06-18 |
2007-09-05 |
株式会社大塚製薬工場 |
ホスホン酸ジエステル誘導体
|
AU6909600A
(en)
|
1999-08-13 |
2001-03-13 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
|
AR035016A1
(es)
|
1999-08-25 |
2004-04-14 |
Takeda Chemical Industries Ltd |
Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6906063B2
(en)
|
2000-02-04 |
2005-06-14 |
Portola Pharmaceuticals, Inc. |
Platelet ADP receptor inhibitors
|
GB0008264D0
(en)
|
2000-04-04 |
2000-05-24 |
Smithkline Beecham Plc |
Novel method and compounds
|
US6500628B1
(en)
|
2000-05-25 |
2002-12-31 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor
|
WO2001096298A2
(en)
|
2000-06-14 |
2001-12-20 |
Warner-Lambert Company |
1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase
|
WO2002000647A1
(en)
|
2000-06-23 |
2002-01-03 |
Bristol-Myers Squibb Pharma Company |
Heteroaryl-phenyl substituted factor xa inhibitors
|
ATE542805T1
(de)
|
2000-08-11 |
2012-02-15 |
Nippon Chemiphar Co |
Ppar-delta aktivatoren
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
US20020173507A1
(en)
|
2000-08-15 |
2002-11-21 |
Vincent Santora |
Urea compounds and methods of uses
|
US20040067938A1
(en)
|
2000-09-29 |
2004-04-08 |
Penglie Zhang |
Quaternary amines and related inhibitors of factor xa
|
US20040058903A1
(en)
|
2000-10-05 |
2004-03-25 |
Hisashi Takasugi |
Benzamide compounds as apo b secretion inhibitors
|
WO2002060869A2
(en)
|
2000-10-19 |
2002-08-08 |
Smithkline Beecham Corporation |
Use of p38 inhibitors for the treatment of inflammation-enhanced cough
|
PL209733B1
(pl)
|
2000-10-27 |
2011-10-31 |
Novartis Ag |
Zastosowanie 4-(4-metylopiperazyno-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]benzamidu w leczeniu żołądkowo-jelitowych guzów podścieliskowych
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
JP2002226464A
(ja)
|
2001-01-30 |
2002-08-14 |
Sumitomo Pharmaceut Co Ltd |
トリアリール類縁体およびその利用
|
WO2002066442A1
(en)
|
2001-02-15 |
2002-08-29 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
|
WO2002070662A2
(en)
|
2001-03-02 |
2002-09-12 |
Gpc Biotech Ag |
Three hybrid assay system
|
JP2004536845A
(ja)
|
2001-07-11 |
2004-12-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介疾患の治療方法
|
EP1281399A3
(en)
|
2001-08-01 |
2004-02-11 |
Warner-Lambert Company |
Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
|
EP1427412A1
(en)
|
2001-09-13 |
2004-06-16 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Methods of treating cytokine mediated diseases
|
SI1450799T1
(sl)
|
2001-12-03 |
2007-02-28 |
Bayer Pharmaceuticals Corp |
Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov
|
TW200303302A
(en)
|
2001-12-19 |
2003-09-01 |
Atherogenics Inc |
Chalcone derivatives and their use to treat diseases
|
AU2003207961A1
(en)
|
2002-01-16 |
2003-07-30 |
Ramot At Tel Aviv University Ltd. |
Compositions and their use for enhancing and inhibiting fertilization
|
CA2472028C
(en)
|
2002-02-01 |
2010-03-30 |
Pfizer Products Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
|
KR100758045B1
(ko)
|
2002-02-01 |
2007-09-11 |
화이자 프로덕츠 인크. |
압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
|
WO2003068223A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
US20030216396A1
(en)
|
2002-02-11 |
2003-11-20 |
Bayer Corporation |
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
|
PT1478358E
(pt)
|
2002-02-11 |
2013-09-11 |
Bayer Healthcare Llc |
Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
|
ES2299689T3
(es)
|
2002-02-25 |
2008-06-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas.
|
EP1480976B1
(en)
|
2002-02-28 |
2007-09-19 |
F.Hoffmann-La Roche Ag |
Thiazole derivatives as npy receptor antagonists
|
US6995144B2
(en)
|
2002-03-14 |
2006-02-07 |
Eisai Co., Ltd. |
Nitrogen containing heterocyclic compounds and medicines containing the same
|
US20030225089A1
(en)
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
US20060063782A1
(en)
|
2002-07-03 |
2006-03-23 |
Murray Christopher W |
3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
|
US20040138216A1
(en)
|
2002-12-23 |
2004-07-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
|
WO2005024755A2
(en)
|
2002-12-31 |
2005-03-17 |
Deciphera Pharmaceuticals, Llc. |
Medicaments for the treatment of neurodegenerative disorders or diabetes
|
US20040171075A1
(en)
|
2002-12-31 |
2004-09-02 |
Flynn Daniel L |
Modulation of protein functionalities
|
US20080045706A1
(en)
|
2002-12-31 |
2008-02-21 |
Flynn Daniel L |
Anti-inflammatory medicaments
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
US7279576B2
(en)
|
2002-12-31 |
2007-10-09 |
Deciphera Pharmaceuticals, Llc |
Anti-cancer medicaments
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
ATE489379T1
(de)
|
2003-02-28 |
2010-12-15 |
Bayer Healthcare Llc |
2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
|
CA2516627A1
(en)
|
2003-02-28 |
2004-09-16 |
Bayer Pharmaceuticals Corporation |
Substituted pyridine derivatives useful in the treatment of cancer and other disorders
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
WO2004113352A1
(en)
|
2003-06-19 |
2004-12-29 |
Amedis Pharmaceuticals Ltd. |
Silylated heterocyclylurea derivatives as cytokine-inhibitors
|
WO2005002673A1
(en)
|
2003-07-03 |
2005-01-13 |
Astex Therapeutics Limited |
Raf kinase inhibitors
|
WO2005012254A1
(en)
|
2003-07-22 |
2005-02-10 |
Arena Pharmaceuticals, Inc. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
AU2004279427B2
(en)
|
2003-10-08 |
2008-07-03 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
WO2005048953A2
(en)
|
2003-11-13 |
2005-06-02 |
Ambit Biosciences Corporation |
Amide derivatives as kinase modulators
|
US20070191336A1
(en)
|
2003-12-24 |
2007-08-16 |
Flynn Daniel L |
Anti-inflammatory medicaments
|
US20080220497A1
(en)
|
2003-12-24 |
2008-09-11 |
Flynn Daniel L |
Modulation of protein functionalities
|
US7812176B2
(en)
|
2004-03-23 |
2010-10-12 |
Arena Pharmaceuticals, Inc. |
Processes for preparing substituted N-aryl-N′-[3-(1H-pyrazol-5-YL) phenyl] ureas and intermediates thereof
|
ATE517885T1
(de)
|
2004-04-30 |
2011-08-15 |
Bayer Healthcare Llc |
Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
|
CA2572331A1
(en)
|
2004-07-02 |
2006-02-09 |
Exelixis, Inc. |
C-met modulators and method of use
|
EP1786422A2
(en)
|
2004-08-16 |
2007-05-23 |
Prosidion Limited |
Aryl urea derivatives for treating obesity
|
SI1789390T1
(sl)
|
2004-09-02 |
2012-05-31 |
Genentech Inc |
Piridilni inhibitorji hedgehog signalizacije
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
CA2584185C
(en)
|
2004-10-13 |
2014-07-15 |
Frank Stieber |
Heterocyclic substituted bisarylurea derivates as kinase inhibitors
|
WO2006046552A1
(ja)
|
2004-10-27 |
2006-05-04 |
Toyama Chemical Co., Ltd. |
新規な含窒素複素環化合物およびその塩
|
GT200500321A
(es)
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
US7612200B2
(en)
|
2004-12-07 |
2009-11-03 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
EP2942349A1
(en)
|
2004-12-23 |
2015-11-11 |
Deciphera Pharmaceuticals, LLC |
Enzyme modulators and treatments
|
US20090312349A1
(en)
|
2004-12-23 |
2009-12-17 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
GB0500435D0
(en)
|
2005-01-10 |
2005-02-16 |
Novartis Ag |
Organic compounds
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
CA2594563A1
(en)
|
2005-01-19 |
2006-07-27 |
Arena Pharmaceuticals, Inc. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
|
AR052886A1
(es)
|
2005-01-26 |
2007-04-11 |
Arena Pharm Inc |
Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis
|
US9265731B2
(en)
|
2005-01-28 |
2016-02-23 |
Bend Research, Inc. |
Drying of drug-containing particles
|
MX2007011041A
(es)
|
2005-03-10 |
2008-02-22 |
Cgi Pharmaceuticals Inc |
Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
|
DE102005015253A1
(de)
|
2005-04-04 |
2006-10-05 |
Merck Patent Gmbh |
Pyrazolderivate
|
CN101287707A
(zh)
|
2005-10-13 |
2008-10-15 |
德福根有限公司 |
激酶抑制剂
|
JP2009518298A
(ja)
|
2005-12-01 |
2009-05-07 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌治療に有用な尿素化合物
|
TW200804349A
(en)
|
2005-12-23 |
2008-01-16 |
Kalypsys Inc |
Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
|
WO2007081690A2
(en)
|
2006-01-04 |
2007-07-19 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
EP2004631A1
(en)
|
2006-04-12 |
2008-12-24 |
Merck Patent GmbH |
N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
|
US7951819B2
(en)
|
2006-04-26 |
2011-05-31 |
Cancer Research Technology Limited |
Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
WO2007136465A2
(en)
|
2006-05-15 |
2007-11-29 |
Irm Llc |
Compositions and methods for fgf receptor kinases inhibitors
|
WO2007137107A2
(en)
|
2006-05-19 |
2007-11-29 |
Abbott Laboratories |
Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
|
US20100160292A1
(en)
|
2006-09-11 |
2010-06-24 |
Cgi Pharmaceuticals, Inc |
Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
|
US7897762B2
(en)
|
2006-09-14 |
2011-03-01 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of proliferative diseases
|
US8188113B2
(en)
|
2006-09-14 |
2012-05-29 |
Deciphera Pharmaceuticals, Inc. |
Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
CN101516379A
(zh)
|
2006-09-14 |
2009-08-26 |
迪赛孚尔制药有限公司 |
可用于治疗增殖性疾病的激酶抑制剂
|
US20120225057A1
(en)
|
2006-10-11 |
2012-09-06 |
Deciphera Pharmaceuticals, Llc |
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
|
US7790756B2
(en)
|
2006-10-11 |
2010-09-07 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
EA200900573A1
(ru)
|
2006-10-20 |
2009-10-30 |
АйАрЭм ЭлЭлСи |
Композиции и способы для модуляции рецепторов c-kit и pdgfr
|
US20080248548A1
(en)
|
2007-04-09 |
2008-10-09 |
Flynn Daniel L |
Modulation of protein functionalities
|
US20080248487A1
(en)
|
2007-04-09 |
2008-10-09 |
Flynn Daniel L |
Modulation of protein functionalities
|
PL2139484T3
(pl)
|
2007-04-10 |
2013-12-31 |
Exelixis Inc |
Sposoby leczenia raka z zastosowaniem pirydopirymidynonów jako inhibitorów PI3K alfa
|
AU2008242720A1
(en)
|
2007-04-20 |
2008-10-30 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
US20110189167A1
(en)
|
2007-04-20 |
2011-08-04 |
Flynn Daniel L |
Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
|
US20100286215A1
(en)
|
2007-09-04 |
2010-11-11 |
Bis-Aromatic Compounds Useful In The Treatment Of Inflammation |
Bis-aromatic compounds useful in the treatment of inflammation
|
US8389567B2
(en)
|
2007-12-12 |
2013-03-05 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CA2714700C
(en)
|
2008-02-22 |
2013-07-30 |
Irm Llc |
Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
|
TWI438205B
(zh)
|
2008-03-05 |
2014-05-21 |
Methylgene Inc |
蛋白質酪胺酸激酶活性抑制劑
|
US20090281089A1
(en)
|
2008-04-11 |
2009-11-12 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
US20110071197A1
(en)
|
2008-04-16 |
2011-03-24 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
US20110112193A1
(en)
|
2008-05-14 |
2011-05-12 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
WO2010011837A1
(en)
|
2008-07-24 |
2010-01-28 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
MX2011004535A
(es)
|
2008-10-29 |
2011-11-18 |
Deciphera Pharmaceuticals Llc |
Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
|
EP3130396B1
(en)
|
2009-03-27 |
2021-03-17 |
Bend Research, Inc. |
Spray-drying process
|
WO2010124283A2
(en)
|
2009-04-24 |
2010-10-28 |
The Jackson Laboratory |
Methods and compositions relating to hematologic malignancies
|
CN102459249A
(zh)
|
2009-05-22 |
2012-05-16 |
埃克塞里艾克西斯公司 |
作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用与制造方法
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
US20110237563A1
(en)
|
2010-03-23 |
2011-09-29 |
Dominique Costantini |
Fast dissolving drug delivery systems
|
US20130023587A1
(en)
|
2010-04-01 |
2013-01-24 |
Duke University |
Compositions and methods for the treatment of cancer
|
CN103068384B
(zh)
|
2010-04-29 |
2015-03-11 |
德西费拉制药有限责任公司 |
表现出抗癌和抗增生活性的环丙基二甲酰胺以及类似物
|
US8569319B2
(en)
|
2010-04-29 |
2013-10-29 |
Deciphera Pharmaceuticals, LLS |
Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
EP2594566A4
(en)
|
2010-07-16 |
2014-10-01 |
Kyowa Hakko Kirin Co Ltd |
AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
|
WO2012035131A1
(en)
|
2010-09-16 |
2012-03-22 |
University Of Zurich |
Treatment of abl overexpressing b-cell lymphoma
|
EP2618924A1
(en)
|
2010-09-24 |
2013-07-31 |
Bend Research, Inc. |
High-temperature spray drying process and apparatus
|
WO2012059526A1
(en)
|
2010-11-05 |
2012-05-10 |
Ab Science |
Treatment of mastocytosis with masitinib
|
EA201390766A1
(ru)
|
2010-11-24 |
2013-11-29 |
Экселиксис, Инк. |
БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
|
KR20140053836A
(ko)
|
2011-01-11 |
2014-05-08 |
글락소스미스클라인 엘엘씨 |
조합물
|
AU2012240240A1
(en)
|
2011-04-04 |
2013-05-09 |
Netherlands Cancer Institute |
Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
|
CN102731385A
(zh)
|
2011-04-08 |
2012-10-17 |
湖南有色凯铂生物药业有限公司 |
3-氯-及3-甲氧基-n-甲基-2-吡啶酰胺化合物及其作为抗癌药物的应用
|
EA028452B1
(ru)
|
2011-07-29 |
2017-11-30 |
Медивейшн Простейт Терапьютикс, Инк. |
Лечение рака молочной железы
|
WO2013036232A2
(en)
|
2011-09-08 |
2013-03-14 |
Deciphera Pharmaceuticals, Llc |
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
|
AU2013201121A1
(en)
|
2011-09-20 |
2013-04-04 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
KR102000312B1
(ko)
*
|
2011-10-14 |
2019-07-15 |
어레이 바이오파마 인크. |
Erb2 (her2) 저해제의 고체 분산물
|
WO2013078295A2
(en)
|
2011-11-22 |
2013-05-30 |
Deciphera Pharmaceuticals, Llc |
Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
KR101338510B1
(ko)
|
2011-12-09 |
2013-12-11 |
포항공과대학교 산학협력단 |
아미노퀴놀론 화합물을 포함하는 간염, 간경변, 또는 간암의 예방 또는 치료용 의약 조성물
|
AR090151A1
(es)
|
2012-03-07 |
2014-10-22 |
Lilly Co Eli |
Compuestos inhibidores de raf
|
US9187474B2
(en)
|
2012-03-07 |
2015-11-17 |
Deciphera Pharmaceuticals, Llc |
Raf inhibitor compounds
|
PL3400943T3
(pl)
*
|
2012-03-23 |
2021-06-14 |
Array Biopharma, Inc. |
Związki do zastosowania w leczeniu przerzutów do mózgu u pacjenta z nowotworem piersi erbb2+
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
WO2013177420A2
(en)
|
2012-05-23 |
2013-11-28 |
St. Jude Children's Research Hospital |
Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
CN104902895B
(zh)
|
2012-06-07 |
2019-03-29 |
德西费拉制药有限责任公司 |
可用作用于治疗增生性疾病的激酶抑制剂的二氢萘啶和相关化合物
|
CA2879431A1
(en)
|
2012-07-17 |
2014-01-23 |
Washington University |
Anti-mucus drugs and uses therefor
|
EP2890380A2
(en)
|
2012-08-29 |
2015-07-08 |
Merck Patent GmbH |
Ddr2 inhibitors for the treatment of osteoarthritis
|
EP2890815B1
(en)
|
2012-08-31 |
2019-03-20 |
The Regents of the University of Colorado |
Methods for diagnosis and treatment of cancer
|
CN104603125A
(zh)
|
2012-09-10 |
2015-05-06 |
弗·哈夫曼-拉罗切有限公司 |
用于治疗和预防乙型肝炎病毒感染的6-氨基酸杂芳基二氢嘧啶
|
WO2014040242A1
(zh)
|
2012-09-12 |
2014-03-20 |
湖南有色凯铂生物药业有限公司 |
3-氯-及3-甲氧基-n-甲基-2-吡啶酰胺化合物及其作为抗癌药物的应用
|
CN103664787B
(zh)
|
2012-09-17 |
2015-09-09 |
南京圣和药业股份有限公司 |
炔杂芳环化合物及其应用
|
US20150275306A1
(en)
|
2012-10-10 |
2015-10-01 |
Stichting Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis |
Methods and means for predicting resistance to anti-cancer treatment
|
FR3000493A1
(fr)
|
2012-12-28 |
2014-07-04 |
Oribase Pharma |
Nouveaux inhibiteurs de proteines kinases
|
FR3000492B1
(fr)
|
2012-12-28 |
2015-09-11 |
Oribase Pharma |
Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
|
US11285169B2
(en)
|
2013-03-13 |
2022-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
CN104045642B
(zh)
|
2013-03-14 |
2016-08-24 |
上海医药工业研究院 |
含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用
|
WO2014145028A2
(en)
|
2013-03-15 |
2014-09-18 |
Deciphera Pharmaceuticals, Llc |
N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
|
US9012635B2
(en)
|
2013-03-15 |
2015-04-21 |
Deciphera Pharmaceuticals, Llc |
Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
US9309224B2
(en)
|
2013-03-15 |
2016-04-12 |
Deciphera Pharmaceuticals, Llc. |
N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
|
US9193719B2
(en)
|
2013-03-15 |
2015-11-24 |
Deciphera Pharmaceuticals, Llc |
1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
|
US9133183B2
(en)
|
2013-03-15 |
2015-09-15 |
Deciphera Pharmaceuticals, Llc |
Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
|
WO2014145025A2
(en)
|
2013-03-15 |
2014-09-18 |
Deciphera Pharmaceuticals, Llc |
2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
|
EP2994140A4
(en)
|
2013-05-07 |
2017-05-03 |
Inhibikase Therapeutics, Inc. |
Methods for treating hcv infection
|
FR3008979B1
(fr)
|
2013-07-23 |
2015-07-24 |
Servier Lab |
Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US10111897B2
(en)
|
2013-10-03 |
2018-10-30 |
Duke University |
Compositions and methods for treating cancer with JAK2 activity
|
WO2015069217A1
(en)
|
2013-11-05 |
2015-05-14 |
Baylor College Of Medicine |
Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
|
US9457019B2
(en)
|
2013-11-07 |
2016-10-04 |
Deciphera Pharmaceuticals, Llc |
Methods for inhibiting tie-2 kinase useful in the treatment of cancer
|
EP3065549A4
(en)
|
2013-11-07 |
2017-05-24 |
Deciphera Pharmaceuticals, LLC |
Methods for inhibiting tie2 kinase useful in the treatment of cancer
|
WO2015076213A1
(ja)
|
2013-11-22 |
2015-05-28 |
独立行政法人国立成育医療研究センター |
急性リンパ芽球性白血病の新規キメラ遺伝子atf7ip-pdgfrb
|
JP6514703B2
(ja)
|
2013-12-20 |
2019-05-15 |
トピバート ファーマ リミテッド |
キナーゼインヒビターとして有用な尿素誘導体
|
WO2015106294A1
(en)
|
2014-01-13 |
2015-07-16 |
Coferon,Inc. |
Bivalent bcr-abl tyrosine kinase ligands, and methods of using same
|
WO2015106292A1
(en)
|
2014-01-13 |
2015-07-16 |
Coferon, Inc. |
Bcr-abl tyrosine-kinase ligands capable of dimerizing in an aqueous solution, and methods of using same
|
US10494417B2
(en)
|
2014-03-25 |
2019-12-03 |
University Of Utah Research Foundation |
Peptide inhibitors of BCR-ABL oligomerization
|
US20170114415A1
(en)
|
2014-05-30 |
2017-04-27 |
The Regents Of The University Of Colorado, A Body Corporate |
Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
|
WO2016022942A1
(en)
|
2014-08-07 |
2016-02-11 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
CN105461699B
(zh)
|
2014-09-25 |
2019-07-09 |
广东东阳光药业有限公司 |
取代的杂环化合物及其使用方法和用途
|
WO2016061231A1
(en)
|
2014-10-14 |
2016-04-21 |
Deciphera Pharmaceuticals, Llc |
Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
|
US20160101090A1
(en)
|
2014-10-14 |
2016-04-14 |
Deciphera Pharmaceuticals, Llc |
Inhibition of trk kinase mediated tumor growth and disease progression
|
US20170360791A1
(en)
|
2014-12-04 |
2017-12-21 |
Astex Pharmaceuticals, Inc. |
Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
|
US20160166679A1
(en)
|
2014-12-12 |
2016-06-16 |
Purdue Research Foundation |
Method of treatment using folate conjugates and tyrosine kinase inhibitors
|
EP3034092A1
(en)
|
2014-12-17 |
2016-06-22 |
Université de Lausanne |
Adoptive immunotherapy for treating cancer
|
WO2016103223A1
(en)
|
2014-12-23 |
2016-06-30 |
Fratagene Therapeutics Ltd. |
Methods of treating friedreich's ataxia using src inhibitors
|
EP3789027A1
(en)
|
2015-01-13 |
2021-03-10 |
Kyoto University |
Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
|
US9637488B2
(en)
|
2015-01-29 |
2017-05-02 |
Fuqiang Ruan |
Heterocyclic compounds as inhibitors of class I PI3KS
|
WO2016135046A1
(en)
|
2015-02-24 |
2016-09-01 |
Academisch Medisch Centrum |
Inhibitors of raf1, mst1, and pkl1 for use in the treatment of a retrovirus
|
WO2016154524A1
(en)
|
2015-03-26 |
2016-09-29 |
Emory University |
Carbonic anhydrase inhibitors and uses related thereto
|
WO2016196141A1
(en)
|
2015-05-29 |
2016-12-08 |
Ignyta, Inc. |
Compositions and methods for treating patients with rtk mutant cells
|
EP3120851A1
(en)
|
2015-07-21 |
2017-01-25 |
Pangaea Biotech S.L. |
4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
|
WO2017042944A1
(ja)
|
2015-09-10 |
2017-03-16 |
国立大学法人山梨大学 |
フィラデルフィア染色体陽性(Ph+)急性リンパ性白血病(ALL)の治療薬又は治療方法
|
CN108366992A
(zh)
|
2015-11-02 |
2018-08-03 |
耶鲁大学 |
蛋白水解靶向嵌合体化合物及其制备和应用方法
|
CA3010101A1
(en)
|
2015-12-29 |
2017-07-06 |
Board Of Regents, The University Of Texas System |
Inhibition of p38 mapk for the treatment of cancer
|
CA3015757A1
(en)
|
2016-02-26 |
2017-08-31 |
Agios Pharmaceuticals, Inc. |
Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
|
WO2017214514A1
(en)
|
2016-06-09 |
2017-12-14 |
Bioxcel Corporation |
Use of src family kinase inhibitor in ribosomal disorder
|
US20190224341A1
(en)
|
2016-06-29 |
2019-07-25 |
The General Hospital Corporation |
Renal clearable organic nanocarriers
|
CN109641056A
(zh)
|
2016-09-13 |
2019-04-16 |
协和发酵麒麟株式会社 |
药物组合物
|
TW201822764A
(zh)
|
2016-09-14 |
2018-07-01 |
美商基利科學股份有限公司 |
Syk抑制劑
|
CA3036384A1
(en)
|
2016-09-14 |
2018-03-22 |
Gilead Sciences, Inc. |
Syk inhibitors
|
JP7098615B2
(ja)
|
2016-12-05 |
2022-07-11 |
フェイト セラピューティクス,インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
CN106822128A
(zh)
|
2017-02-24 |
2017-06-13 |
南华大学附属第医院 |
酪氨酸激酶抑制剂dcc‑2036的新应用
|
WO2018195450A1
(en)
|
2017-04-21 |
2018-10-25 |
Epizyme, Inc. |
Combination therapies with ehmt2 inhibitors
|
CA3065365A1
(en)
|
2017-05-30 |
2018-12-06 |
Daniel L. Flynn |
Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
|
US11802875B2
(en)
|
2017-05-30 |
2023-10-31 |
Albert Einstein College Of Medicine |
Method for treating neoadjuvant chemotherapy-induced metastasis
|
JP7175309B2
(ja)
*
|
2017-10-27 |
2022-11-18 |
プレキシコン インコーポレーテッド |
キナーゼを調節する化合物の製剤
|
JP2021512101A
(ja)
|
2018-01-31 |
2021-05-13 |
デシフェラ・ファーマシューティカルズ,エルエルシー |
肥満細胞症の治療のための併用療法
|
CN108379591B
(zh)
|
2018-04-03 |
2022-03-29 |
深圳大学 |
免疫激动剂靶向化合物的合成及其应用
|
WO2020139828A1
(en)
|
2018-12-28 |
2020-07-02 |
Deciphera Pharmaceuticals, Llc |
Csf1r inhibitors for use in treating cancer
|
WO2020185812A1
(en)
*
|
2019-03-11 |
2020-09-17 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of ripretinib
|
US11530206B2
(en)
|
2019-05-10 |
2022-12-20 |
Deciphera Pharmaceuticals, Llc |
Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
WO2020231808A1
(en)
|
2019-05-10 |
2020-11-19 |
Deciphera Pharmaceuticals, Llc |
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
TW202122082A
(zh)
|
2019-08-12 |
2021-06-16 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
AU2020329956B2
(en)
|
2019-08-12 |
2023-11-16 |
Deciphera Pharmaceuticals, Llc. |
Ripretinib for treating gastrointestinal stromal tumors
|
JP2023509628A
(ja)
|
2019-12-30 |
2023-03-09 |
デシフェラ・ファーマシューティカルズ,エルエルシー |
1-(4-ブロモ-5-(1-エチル-7-(メチルアミノ)-2-オキソ-1,2-ジヒドロ-1,6-ナフチリジン-3-イル)-2-フルオロフェニル)-3-フェニル尿素の組成物
|
BR112022013109A2
(pt)
|
2019-12-30 |
2022-09-06 |
Deciphera Pharmaceuticals Llc |
Formulações de inibidor de quinase amorfo e métodos de uso das mesmas
|
CN114902895B
(zh)
|
2022-04-06 |
2023-12-12 |
安徽科技学院 |
一种基于蔬菜种植的能源回收式大棚
|